R&D News | pharmaphorum

News

Controversial project aims to make artificial human genomes

A landmark project funded by Wellcome aims to develop the tools needed to synthesise human genomes – and simultaneously probe the social implications.

News

Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen

After winding up its stem cell therapy operations last month, Vor Bio has reinvented itself as an autoimmune disease-focused biotech.

News

Nektar eyes pivotal trials for eczema drug cast off by Lilly

Nektar Therapeutics has said phase 2b results show it was right to keep faith with rezpegaldesleukin as a therapy for atopic dermatitis.

News

Could a vaccine adjuvant be protective against dementia?

Scientists behind a study suggesting GSK's RSV vaccine may be protective against dementia have said the adjuvant used in it may be responsible.

News

Biogen races into phase 3 with Spinraza follow-up

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.

News

Kymera signs $750m cancer deal with Gilead as Sanofi opts in

Kymera is celebrating the signing of two partnerships, with Gilead taking an option on one molecular glue programme, as Sanofi buys into another.

Controversial project aims to make artificial human genomes

Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen

Nektar eyes pivotal trials for eczema drug cast off by Lilly

Could a vaccine adjuvant be protective against dementia?

Biogen races into phase 3 with Spinraza follow-up

Kymera signs $750m cancer deal with Gilead as Sanofi opts in

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks